Sociodemographic predictors of the late-stage diagnosis in patients with prostate cancer: A retrospective cohort study.

M Muhammad Ali Khan M Muhammad Umar Afzal (Mayo Clinic Arizona, Scottsdale, AZ) A Ammad Raina (Midwestern University, AZCOM, Glendale, AZ) Z Zaryab Bin Riaz (Division of Internal Medicine, Creighton University School of Medicine – Phoenix, Phoenix, AZ) K Kainat Warraich (Cleveland Clinic, Cleveland, OH) A Alton Oliver Sartor (LCMC Health, New Orleans, LA) A Alan Haruo Bryce (Mayo Clinic Arizona, Phoenix, AZ) P Parminder Singh (Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ) D Daniel S Childs (Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN) J Jacob Orme (Department of Medical Oncology, Mayo Clinic Rochester, Rochester, MN) H Haidar Abdul-Muhsin (Mayo Clinic Arizona, Phoenix, AZ) A Adam McLain Kase (Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL) C Cassandra N. Moore (Mayo Clinic in Arizona, Phoenix, AZ) N Neeraj Agarwal (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) Y Yousef Zakharia (Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA) E Ewan Kemar Cobran (Mayo Clinic College of Medicine and Science, Scottsdale, AZ) I Irbaz Bin Riaz (Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA)

Abstract

132 Background: Distant metastasis at the time of prostate cancer (PCa) diagnosis is associated with increased morbidity and mortality. This study aimed to assess the impact of sociodemographic characteristics on distant metastasis at the time of PCa diagnosis. Methods: The Surveillance Epidemiology and End Results (SEER) database (2000-2021), including PCa patients from 17 registries, was queried. Patients with late-stage diagnosis (LSD) were defined as those who were initially diagnosed with stage IV disease, indicating distant metastasis. Sociodemographic predictors included race, ethnicity, age, marital status, residential status, and median household income. Multicollinearity was assessed using variance inflation factors (VIF). Univariable logistic regression was performed to identify significant predictors of LSD, which were further analyzed in multivariable logistic regression using a maximum likelihood estimation approach. Odds ratios with 95% confidence intervals (CI) were computed with a p-value of <0.05 indicating a statistically significant association. Results: Of the 1,089,736 PCa patients diagnosed, 64,983 (6%) had an LSD. The majority were white (80%), non-Hispanic/Latino (HL) (91%), aged ≥65 years (60%), married (75%), residents in metropolitan areas (88%), and had an annual house income of ≥$70,000 (70%). Multivariable logistic regression identified Black (OR: 1.24; 95%CI: 1.22-1.27), Asian or Pacific Islander (1.35; 1.30-1.40), and American Indian/Alaska Native (1.70; 1.53-1.89) to have higher odds of LSD compared to White patients (Table). In addition, HL ethnicity compared to non-HL (OR: 1.45; 95% CI: 1.42-1.49), age ≥65 compared to <65 (1.68; 1.65-1.71), unmarried status compared to married (1.88; 1.85-1.91), residency in non-metropolitan areas compared to metropolitan (1.10; 1.07-1.12), and household income <$70,000 compared to ≥$70,000 (1.03; 1.01-1.05) had a significant association with LSD. Conclusions: Older, non-White (Black, Asian/Pacific Islander, American Indian/Alaska Native), Hispanic/Latino, unmarried men, residents of non-metropolitan areas, or those with lower annual household incomes have higher odds of late-stage diagnosis. Interventions targeting early detection in these at-risk groups may improve prostate cancer outcomes in the US. Variable Odds Ratio (95% CI) p-value Race (Black vs White) 1.24 (1.22-1.27) <0.01 Race (Asian or Pacific Islander vs White) 1.35 (1.31-1.40) <0.01 Race (American Indian/Alaska Native vs White) 1.70 (1.53-1.89) <0.01 Ethnicity (Hispanic/Latino vs non-/Hispanic/Latino) 1.45 (1.42-1.49) <0.01 Age (≥65 vs <65) 1.68 (1.65-1.71) <0.01 Marital status (unmarried vs married) 1.88 (1.85-1.91) <0.01 Residence status (non-metropolitan vs metropolitan) 1.10 (1.07-1.12) <0.01 Household income (<$70,000 vs ≥$70,000) 1.03 (1.01-1.05) <0.01

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 132-132
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (17)

M

Muhammad Ali Khan

M

Muhammad Umar Afzal

Mayo Clinic Arizona, Scottsdale, AZ

A

Ammad Raina

Midwestern University, AZCOM, Glendale, AZ

Z

Zaryab Bin Riaz

Division of Internal Medicine, Creighton University School of Medicine – Phoenix, Phoenix, AZ

K

Kainat Warraich

Cleveland Clinic, Cleveland, OH

A

Alton Oliver Sartor

LCMC Health, New Orleans, LA

A

Alan Haruo Bryce

Mayo Clinic Arizona, Phoenix, AZ

P

Parminder Singh

Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ

D

Daniel S Childs

Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN

J

Jacob Orme

Department of Medical Oncology, Mayo Clinic Rochester, Rochester, MN

H

Haidar Abdul-Muhsin

Mayo Clinic Arizona, Phoenix, AZ

A

Adam McLain Kase

Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL

C

Cassandra N. Moore

Mayo Clinic in Arizona, Phoenix, AZ

N

Neeraj Agarwal

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

Y

Yousef Zakharia

Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA

E

Ewan Kemar Cobran

Mayo Clinic College of Medicine and Science, Scottsdale, AZ

I

Irbaz Bin Riaz

Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA